Oculis Holding AG (OCS) fair value analysis
Nasdaq · Updated 2026-10-19
OCS price how computed
Valuation status
Reports in CHFOCS reports its results in CHF while its shares trade in US dollars.
Forward Fair Value needs earnings and price in the same currency, so TickrTrends publishes no fair-value verdict for OCS until same-currency inputs are available. Price and market cap below are in US dollars; revenue and EPS are shown in CHF.
- Last price
- $8.76
- Sector
- Healthcare
- 12-month range
- $7.17–$32.65
- Market cap
- $540M
- From 52-week high
- -73.2%
- Shares outstanding
- 61.6M
- Rank in Healthcare by quality score
- #257 of 301
Last price is the 2026-10-01 month-start close, the freshest stored price; the chart runs through 2026-10-16.
Oculis Holding AG is a biopharmaceutical company focused on developing and commercializing therapies for eye diseases and disorders. The company operates internationally with a presence in Switzerland and other markets.
OCS currently ranks #257 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
Revenue and EPS are shown in CHF; the trailing P/E is omitted because an EPS in CHF against a US-dollar share price would mislead.
- Market cap
- $540M
- Revenue (TTM)
- CHF 243K
- Net margin
- -32780.2%
- EPS (TTM)
- CHF -1.43
- Debt / equity
- 0.01
- Revenue growth (3-yr avg)
- -33.3%
- Shares outstanding
- 61.6M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Contracting
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 26 · oversold
- 50-day average
- $10.77
- 200-day average
- $19.51
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-09
- Last 8 quarters vs consensus
- 2 beat, 6 missed
- Quarter by quarter
- 2026-06 ▲ beat (+58.3%)
2026-03 ▼ miss (-19.5%)
2025-12 ▼ miss (-2.1%)
2025-09 ▲ beat (+22.0%)
2025-06 ▼ miss (-8.9%)
2025-03 ▼ miss (-72.5%)
2024-12 ▼ miss (-55.8%)
2024-09 ▼ miss (-14.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 10 buy · 0 hold · 0 sell (10 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $37
- Target vs last price
- +322.4%
What our data shows for OCS
- Shares are trading in the lower third of their 12-month price range of $7.17–$32.65.
- The 14-day relative strength index sits at an oversold 26.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- OCS's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the OCS conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is OCS stock undervalued?
OCS reports its results in CHF while its shares trade in US dollars. Forward Fair Value needs earnings and price in the same currency, so TickrTrends publishes no fair-value verdict for OCS until same-currency inputs are available.
What is OCS's TickrTrends verdict?
OCS is currently marked 'Reports in CHF' - no verdict is published on inputs in two different currencies.
How does OCS compare to other Healthcare stocks?
OCS ranks #257 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is OCS overbought or oversold?
OCS's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does OCS report earnings next?
OCS's next earnings report is scheduled for 2026-11-09, per the published earnings calendar.
Does OCS usually beat earnings estimates?
Over its last 8 reported quarters OCS beat the consensus estimate 2 times and missed 6 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about OCS?
Of 10 analysts covering OCS, 10 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $37 (+322.4% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.